Exelbine Approval Status
- FDA approved: No
- Brand name: Exelbine
- Generic name: vinorelbine
- Dosage form: Injectable Emulsion
- Previous name: ANX-530
- Company: Adventrx Pharmaceuticals, Inc.
- Treatment for: Non-Small Cell Lung Cancer
Exelbine (formerly ANX-530) is a proprietary emulsion formulation of vinorelbine intended to reduce the incidence and severity of vein irritation associated with intravenous delivery of the drug. Exelbine is intended for the treatment of non-small cell lung cancer.
In August 2011, Adventrx Pharmaceuticals, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for Exelbine (vinorelbine) had not been approved.
Development Status and FDA Approval Process for Exelbine
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.